Cardiff Oncology, Inc.CRDFNASDAQ
LOADING
|||
Switch Symbol:
Gross Profit Growth Accelerating
Trending higher, above historical average.
Left:
||||
Year-over-year gross profit growth rate
Latest
101.05%
↑ 100% above average
Average (39q)
-24849.41%
Historical baseline
Range
High:216.28%
Low:-967581.91%
CAGR
NaN%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | 101.05% |
| Q2 2025 | -10612.84% |
| Q1 2025 | -27.81% |
| Q4 2024 | 101.59% |
| Q3 2024 | -16436.21% |
| Q2 2024 | -43.69% |
| Q1 2024 | 94.34% |
| Q4 2023 | 55.88% |
| Q3 2023 | -68.52% |
| Q2 2023 | 30.12% |
| Q1 2023 | -35.16% |
| Q4 2022 | 37.63% |
| Q3 2022 | 2.20% |
| Q2 2022 | 22.97% |
| Q1 2022 | -44.36% |
| Q4 2021 | 54.65% |
| Q3 2021 | 26.47% |
| Q2 2021 | -5.56% |
| Q1 2021 | -39.63% |
| Q4 2020 | -12.31% |
| Q3 2020 | 216.28% |
| Q2 2020 | -36.76% |
| Q1 2020 | -26.55% |
| Q4 2019 | 103.35% |
| Q3 2019 | -2.78% |
| Q2 2019 | -8.27% |
| Q1 2019 | 99.58% |
| Q4 2018 | -967581.91% |
| Q3 2018 | 166.60% |
| Q2 2018 | 65.21% |
| Q1 2018 | -34.45% |
| Q4 2017 | 43.41% |
| Q3 2017 | -48.13% |
| Q2 2017 | 54.70% |
| Q1 2017 | -0.46% |
| Q4 2016 | -54.72% |
| Q3 2016 | -9.60% |
| Q2 2016 | -62.12% |
| Q1 2016 | -57.32% |
| Q4 2015 | -3.26% |